Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 3, 2011, Pages 169-175

  Rao, Ravi P ^a   Jain, A K ^b   Srinivasan, B P ^a  

^a UNIVERSITY OF DELHI   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

Diabetic nephropathy; renin angiotensin system (RAS); TGF 1; TNF ; type 2 diabetes mellitus

Indexed keywords

ALBUMIN; FIBRONECTIN; GLUCOSE; PROTEIN; STREPTOZOCIN; TELMISARTAN; TRANDOLAPRIL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GLUCOSE BLOOD LEVEL; INTERMETHOD COMPARISON; KIDNEY; MALE; MONOTHERAPY; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FASTING; FEMALE; FIBRONECTINS; INDOLES; MALE; RATS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052372118     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320310392097     Document Type: Article

References (36)

1. Khan CR Insulin action, diabetogenesis and the cause of type 2 diabetes. Diabetes 1994 ; 43: 1066-1084.
2. Hasslacher C., Ritz E. and Wahl P. Similar risks of nephropathy in type 1 or type 2 diabetes mellitus. Nephrol Dial Transplant 1989 ; 4: 859-863. (Pubitemid 20031053)
3. Cooper ME Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998 ; 352: 213-19. (Pubitemid 28327814)
4. Caramori ML and Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003 ; 12: 273-282. (Pubitemid 36578062)
5. Mogensen CE, Keane WF, Bennett PH, Jerums G., Parving HH and Passa P. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995 ; 346: 1080-1084.
6. Remuzzi G., Benigni A. and Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006 ; 116: 288-296. (Pubitemid 43228342)
7. Denton KM, Anderson WP and Sinniah R. Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole. Am J Physiol Regul Integr Comp Physiol 2000 ; 279: 629-638.
8. Mitchell KD, Braam B. and Navar LG Hypertensiogenic mechanisms mediated by renal actions of renin-angiotensin system. Hypertension 1992 ; 19: 18-27.
9. Lebovitz HE, Wiegmann TB, Cnaan A., Shahinfar S., Sica DA and Broadstone V. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994 ; 45: S150 - S155.
10. Bakris GL Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990 ; 112: 707-708. (Pubitemid 20137180)
11. Fogari R., Zoppi A., Corradi L., Mugellini A., Lazzari P. and Preti P. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999 ; 13: 47-53. (Pubitemid 29042145)
12. Parving HH, Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S. and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 ; 345: 870-878.
13. Brenner BM, Cooper ME, DeZeeuw D., Keane WF, Mitch WE and Parving HH Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 ; 345: 861-869.
14. Lewis EJ, Hunsicker LG, Clarke WR, Berl T., Pohl MA and Lewis JB Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 ; 345: 851-860.
15. Thomas S. and Viberti G. Diabetic nephropathy. Medicine 2006 ; 34: 83-86. (Pubitemid 44882648)
16. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983 ; 309: 1543-1546. (Pubitemid 14212836)
17. Yamamoto T., Nakamura T., Noble NA, Ruoslahti E. and Border WA Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993 ; 90: 1814-1818. (Pubitemid 23069947)
18. Mulay SR, Gaikwad AB and Tikoo K. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/ smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Chem Biol Interact 2010 ; 185: 137-142.
19. Ozata M., Kurt I., Azal O., Bolu E., Corakci A., Beyhan Z., et al. Can we use plasma fibronectin levels as a marker for early diabetic nephropathy? Endocrinol J 1995 ; 42: 301-305.
20. Hasegawa G., Nakano K., Sawada M., Uno K., Shibayama Y., Lenaga K., Kondo M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991 ; 40: 1007-1012.
21. Bonner-Weir S., Trent DF, Honey RN, Weir GC Response to neonatal islets to streptozocin, limited beta cell regeneration and hyperglycemia. Diabetes 1981 ; 30: 590-595.
22. Sharma AK, Srinivasan BP Triple versus glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Euro J Pharm Sci 2009 ; 38: 433-444.
23. Blay M., Peinado-On S., Grasa MM, Diaz-silva M., Fernandez-Lopez JA and Remesar X. Effect of oral oleoyl-estrone treatment on plasma lipoproteins and tissue lipase activities of Zuker lean and obese female rats. Int J Obes 2002 ; 26: 618-626. (Pubitemid 34499280)
24. Kitamura N., Takahashi Y., Yamadate S. and Asai S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2007 ; 6: 26.
25. Benson SC, Pershadsingh HA, Ho CI, Avery MA, Kurtz TW Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ modulating activity. Hypertension 2004 ; 43: 993-1002. (Pubitemid 38579904)
26. Border WA and Noble NA Interaction of transforming growth factor beta and angiotensin II in renal fibrosis. Hypertension 1998 ; 31: 83-97.
27. Wang SN and Hirschberg R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 2000 ; 278: F554 - F560. (Pubitemid 30215232)
28. Parving HH Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998 ; 41: 745-759.
29. De Jong PE, Navis GJ and De Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999 ; 354: 352-353. (Pubitemid 29355744)
30. Eijkelkamp WB, Zhang Z., Remuzzi G., Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial. J Am Soc Nephrol 2007 ; 18: 1540-1546. (Pubitemid 46717521)
31. Kalantarinia K. and Okusa MD The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Curr Diab Rep 2006 ; 6: 8-16.
32. Wolf G. and Ziyadeh FN Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999 ; 56: 393-405. (Pubitemid 29353136)
33. Houlihan CA, Akdeniz A., Tsalamandris C., Cooper ME, Jerums G. and Gilbert RE Urinary transforming growth factor-β excretion in patients with hypertension. Type 2 diabetes and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002 ; 25: 1072-1077. (Pubitemid 41110496)
34. Hasegawa G., Nakano K. and Kondo M. Role of TNF and IL-1 in the development of diabetic nephropathy. Nefrologia 1995 ; 15: 1-4.
35. Baud L., Fouqueray B., Philippe C. and Amram A. Tumor necrosis factor α and mesangial cells. Kidney Int 1992 ; 41: 600-603.
36. Egido J., Gomez-Chiari M., Ortiz A., Bustos C., Alonso J., Gomez-Guerrero C., et al. Role of tumor necrosis factor-α in the pathogenesis of glomerular diseases. Kidney Int 1993 ; 43: S59 - S64.